By Josh White
Date: Tuesday 19 Aug 2025
(Sharecast News) - Cambridge Cognition said on Tuesday that Monument Therapeutics, in which it holds a 20% stake, has partnered with the Foundation for the National Institutes of Health to trial a new treatment for schizophrenia.
By Iain Gilbert
Date: Thursday 10 Apr 2025
(Sharecast News) - Software group Cambridge Cognition said on Thursday that it has secured a £1.0m contract to provide digital cognitive assessments for a large Phase 3 autoimmune disease clinical trial.
By Josh White
Date: Wednesday 08 Jan 2025
(Sharecast News) - Cambridge Cognition announced the use of its 'CANTAB' cognitive assessment product in two phase three clinical trials conducted by Bristol Myers Squibb for 'Cobenfy', a newly FDA-approved treatment for schizophrenia.
| Currency | UK Pounds |
| Share Price | 34.00p |
| Change Today | 0.000p |
| % Change | 0.00 % |
| 52 Week High | 46.00 |
| 52 Week Low | 25.00 |
| Volume | 10,228 |
| Shares Issued | 46.63m |
| Market Cap | £15.85m |
| Beta | 0.50 |
| RiskGrade | 282 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| Strong Buy | 1 |
| Buy | 1 |
| Neutral | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 2 |

| No dividends found |
| Time | Volume / Share Price |
| 15:12 | 10,000 @ 33.05p |
| 14:39 | 102 @ 33.00p |
| 14:38 | 126 @ 33.00p |
You are here: research